GDF15/MIC-1 Functions As a Protective and Antihypertrophic Factor Released From the Myocardium in Association With SMAD Protein Activation

Abstract

Abstract-Here we identified growth-differentiation factor 15 (GDF15) (also known as MIC-1), a secreted member of the transforming growth factor (TGF)-␤ superfamily, as a novel antihypertrophic regulatory factor in the heart. GDF15 is not expressed in the normal adult heart but is induced in response to conditions that promote hypertrophy and dilated cardiomyopathy. To elucidate the function of GDF15 in the heart, we generated transgenic mice with cardiac-specific overexpression. GDF15 transgenic mice were normal but were partially resistant to pressure overload-induced hypertrophy. Expression of GDF15 in neonatal cardiomyocyte cultures by adenoviral-mediated gene transfer antagonized agonist-induced hypertrophy in vitro. Transient expression of GDF15 outside the heart by intravenous adenoviral delivery, or by direct injection of recombinant GDF15 protein, attenuated ventricular dilation and heart failure in muscle lim protein gene-targeted mice through an endocrine effect. Conversely, examination of Gdf15 gene-targeted mice showed enhanced cardiac hypertrophic growth following pressure overload stimulation. Gdf15 gene-targeted mice also demonstrated a pronounced loss in ventricular performance following only 2 weeks of pressure overload stimulation, whereas wild-type controls maintained function. Mechanistically, GDF15 stimulation promoted activation of SMAD2/3 in cultured neonatal cardiomyocytes. Overexpression of SMAD2 attenuated cardiomyocyte hypertrophy similar to GDF15 treatment, whereas overexpression of the inhibitory SMAD proteins, SMAD6/7, reversed the antihypertrophic effects of GDF15. These results identify GDF15 as a novel autocrine/endocrine factor that antagonizes the hypertrophic response and loss of ventricular performance, possibly through a mechanism involving SMAD proteins. Key Words: cardiac Ⅲ signaling Ⅲ hypertrophy Ⅲ growth factors Ⅲ mouse genetics C ardiac hypertrophy is typically characterized by an enlargement of the heart associated with an increase in cardiomyocyte cell volume that occurs during postnatal development, in response to physiologic stimuli such as exercise and in response to diverse pathophysiological stimuli such as hypertension, ischemic heart disease, valvular insufficiency, infectious agents, or mutations in sarcomeric genes. 1 Pathologic hypertrophic growth of the myocardium is a leading predictor for the development of arrhythmias and sudden death, as well as dilated cardiomyopathy and heart failure. 2,3 In general, the hypertrophic growth of the myocardium is regulated by endocrine, paracrine, and autocrine growth factors that activate membrane-bound receptors resulting in signal transduction that culminates in altered gene transcription and protein accumulation. 4 Both pro-and antihypertrophic growth factors have been characterized. For example, angiotensin II (Ang II) serves as an endocrine and autocrine growth factor underlying pathological cardiac hypertrophy, whereas insulin-like growth factor (IGF)-1 signaling is thought to function, in part, by mediating deve...

Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: A potential marker of erosive joint destruction

“…MIC-1 has not been widely studied in inflammation; however, we found that serum levels of MIC-1 independently predicted atherosclerotic events (20), and MIC-1 itself is associated with tissue remodeling in cardiac damage (30). Like RA, atherosclerosis is a macrophage-mediated chronic inflammatory disease.…”

Fator de diferenciação de crescimento 15: um novo biomarcador em pacientes com disfunção diastólica?

“…Experimental studies have shown that GDF-15 expression significantly increases in the heart after various forms of stress, including pressure overload 22,23 . Animal studies have shown that GDF-15 promotes protective, antiapoptotic and antihypertrophic effects in the heart 23 .…”

“…Animal studies have shown that GDF-15 promotes protective, antiapoptotic and antihypertrophic effects in the heart 23 . Considering the fact that GDF-15 is produced by several other cell types in addition to cardiomyocytes (endothelial cells, adipocytes, macrophages, vascular smooth muscle cells), it is likely that this biomarker integrates information from different disease pathways, providing a pathophysiological insight in patients with HFnEF.…”

Dynamics of Heart Failure Markers in Patients after Past Myocardial Infarction with the Use of Potassium and Magnesium Salts of Gluconic Acid, Eplerenone and Rivaroxaban

“…Retrospective study analyses have shown that high levels of GDF-15 are associated with increased risk of death and/or repeated AMI [14]. According to some data, this biomarker is a more accurate marker of CHF with preserved left ventricular (LV) ejection fraction while natriuretic peptide (NUP) better shows the course of systolic heart failure [15].The level of GDF-15 correlates with the severity of CHF manifestations and LV diastolic dysfunction indices [8].…”